Literature DB >> 24094895

Osteonecrosis of the jaw related to everolimus: a case report.

Dong Wook Kim1, Young-Soo Jung, Hyung-Sik Park, Hwi-Dong Jung.   

Abstract

Antiresorptive agent-related osteonecrosis of the jaw results in appreciable morbidity in affected patients. Nowadays many physicians prescribe an antiangiogenic agent for the management of malignant metastases. Everolimus is a serine-threonine kinase that acts as an inhibitor of mammalian target of rapamycin, which results in reduced growth of cells, angiogenesis, and survival of cells. We report the first case to our knowledge of osteonecrosis of the jaw that seemed to result from the additive effect of everolimus.
Copyright © 2013 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ARONJ; Anti-angiogenic agent; Anti-resorptive agent related osteonecrosis of the jaw; Everolimus

Mesh：

Substances：

Year:  2013        PMID： 24094895     DOI： 10.1016/j.bjoms.2013.09.008

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN： 0266-4356            Impact factor:   1.651


  16 in total

1.  Osteonecrosis of the jaw associated with ziv-aflibercept.

Authors:  Hani Mawardi; Peter Enzinger; Nadine McCleary; Reshma Manon; Alessandro Villa; Nathaniel Treister; Sook-Bin Woo
Journal:  J Gastrointest Oncol       Date:  2016-12

2.  The Prevention of Medication-related Osteonecrosis of the Jaw.

Authors:  Philipp Poxleitner; Monika Engelhardt; Rainer Schmelzeisen; Pit Voss
Journal:  Dtsch Arztebl Int       Date:  2017-02-03       Impact factor: 5.594

Review 3.  Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.

Authors:  Emmanuelle Vigarios; Joel B Epstein; Vincent Sibaud
Journal:  Support Care Cancer       Date:  2017-02-22       Impact factor: 3.603

4.  Osteonecrosis of the jaw associated with everolimus: A case report.

Authors:  Daigo Yamamoto; Yu Tsubota; Toshiki Utsunomiya; Noriko Sueoka; Aiko Ueda; Kayoko Endo; Katsuhiro Yoshikawa; Masanori Kon
Journal:  Mol Clin Oncol       Date:  2016-12-05

5.  Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Authors:  Ourania Nicolatou-Galitis; Maria Kouri; Erofili Papadopoulou; Emmanouil Vardas; Dimitra Galiti; Joel B Epstein; Sharon Elad; Giuseppina Campisi; Nikolaos Tsoukalas; Kivanc Bektas-Kayhan; Winston Tan; Jean-Jacques Body; Cesar Migliorati; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2018-10-23       Impact factor: 3.603

6.  Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases.

Authors:  Tara L Aghaloo; Sotirios Tetradis
Journal:  J Oral Maxillofac Surg       Date:  2016-07-30       Impact factor: 1.895

7.  Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?

Authors:  Kezban Nur Pilanci; Gul Alco; Cetin Ordu; Dauren Sarsenov; Filiz Celebi; Zeynep Erdogan; Filiz Agacayak; Serkan Ilgun; Coskun Tecimer; Gokhan Demir; Yesim Eralp; Sait Okkan; Vahit Ozmen
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

Review 8.  Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches.

Authors:  Thomas Lombard; Virginie Neirinckx; Bernard Rogister; Yves Gilon; Sabine Wislet
Journal:  Stem Cells Int       Date:  2016-09-18       Impact factor: 5.443

9.  A Case of Pentastomiasis at the Left Maxilla Bone in a Patient with Thyroid Cancer.

Authors:  Eunae Sandra Cho; Seung Wook Jung; Hwi-Dong Jung; In Yong Lee; Tai-Soon Yong; Su Jin Jeong; Hyun Sil Kim
Journal:  Korean J Parasitol       Date:  2017-08-31       Impact factor: 1.341

10.  Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature.

Authors:  F Longo; A Guida; C Aversa; E Pavone; G Di Costanzo; L Ramaglia; F Ionna
Journal:  Int J Dent       Date:  2014-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.